Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. (Nasdaq: JAGX) filed a Form S-3 shelf registration statement dated June 20, 2025. The filing registers up to 507,390 shares of common stock for resale by existing security holders: (i) 492,612 shares underlying outstanding common warrants and (ii) 14,778 shares underlying placement-agent warrants issued in a May 22, 2025 private placement.
Key warrant terms:
- Common Warrants: exercisable immediately at $5.84 per share; expiration is the earlier of 24 months from issuance, a fundamental transaction, or a liquidation event.
- Placement-Agent Warrants: exercisable immediately at $7.6125 per share; same maturity framework as the common warrants.
The company qualifies as a non-accelerated filer and a smaller reporting company; it is not an emerging-growth company. Jaguar will receive no proceeds from stockholder resales, but will obtain cash only upon warrant exercise. The last reported Nasdaq closing price on June 18, 2025 was $2.78—well below both exercise prices—so immediate exercise is unlikely absent a price increase.
The prospectus highlights the company’s commercial focus on plant-based gastrointestinal therapeutics, including crofelemer (Phase 3 OnTarget study) and the recently in-licensed Gelclair product. Investors are directed to the company’s Form 10-K for the year ended December 31, 2024 (filed March 31 and amended April 15, 2025) for a full risk discussion.
Use of proceeds: none from resales; potential, unspecified proceeds from future cash exercises of the warrants.